Using statins to prevent organ transplant rejection
Targeting the transcriptional co-activators YAP and TAZ with statins to prevent solid organ transplant rejection by HLA donor specific antibodies
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10890862
This study is looking at how statins might help prevent organ transplant rejection by targeting certain proteins in the immune system, which could lead to better outcomes for patients who have received transplants.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10890862 on ClinicalTrials.gov |
What this research studies
This research investigates how statins can target specific proteins involved in the immune response to prevent rejection of solid organ transplants. It focuses on understanding the role of certain transcriptional co-activators, YAP and TAZ, in the development of harmful antibodies that can lead to transplant failure. By exploring the mechanisms behind these antibodies, the research aims to develop new therapeutic strategies to improve transplant outcomes for patients. Patients who have received organ transplants may benefit from this innovative approach to enhance graft survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone solid organ transplantation and are at risk of developing donor-specific antibodies.
Not a fit: Patients who have not received an organ transplant or those who do not exhibit risk factors for antibody-mediated rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of organ transplant rejection and improve long-term transplant success rates.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways to improve transplant outcomes, indicating that this approach has potential for success.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REED, ELAINE F — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: REED, ELAINE F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.